Mizuho raised target for Haemonetics stock to USD 140.00

Published on 10/20/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haemonetics reports second-quarter results on November 5, 2026. Haemonetics stock costs EUR 105.50 on October 20, 2026, versus USD 118.83 on NYSE.

Analyst target and reporting date

Mizuho raised its Haemonetics target from USD 95.00 to USD 140.00 on October 9, 2026.
Haemonetics plans to publish fiscal second-quarter 2027 results on November 5, 2026.
Haemonetics stock costs EUR 105.50 at Lang & Schwarz on October 20, 2026 at 7:47 p.m. CEST.

HAE, US4050241003, Illustration mit AI erstellt.

Mizuho raised its Haemonetics target from USD 95.00 to USD 140.00 on October 9, 2026, according to Markets Insider. The revision followed updated terms for Haemonetics equipment and disposable products at CSL Plasma. Mizuho's target lies 17.81 percent above the USD 118.83 NYSE price on October 20, 2026 at 1:52 p.m. EDT. At Lang & Schwarz, Haemonetics stock was trading at EUR 105.50 on October 20, 2026 at 7:47 p.m. CEST.

Target reflects CSL expansion

Mizuho's note linked the higher target to CSL's plan to convert all of its U.S. centers to Haemonetics equipment and disposables by the end of 2027. The analyst estimated USD 400.00 million in sales and USD 2.35 in adjusted earnings per share from the updated terms, as reported by Markets Insider.

Quarterly figures set the baseline

Haemonetics reported USD 339.38 million in revenue for fiscal first-quarter 2027, up 5.50 percent from the prior year, while adjusted earnings per share reached USD 1.14 versus a USD 1.08 consensus estimate. Transcript Daily reported the figures on October 14, 2026, citing the results released on August 6, 2026.

What does the next report add?

Haemonetics intends to publish fiscal second-quarter 2027 results at 6:00 a.m. ET on November 5, 2026, followed by an earnings call at 8:00 a.m. ET, according to the company's Haemonetics Corporation. The call should provide the next quantified update on fiscal 2027 guidance and the CSL rollout.

Comparison with peers

Becton, Dickinson and Company (NYSE, USD): up 1.45 percent, P/E 58.29, market capitalization USD 52.7 billion on October 20, 2026.
The Cooper Companies (NYSE, USD): up 1.47 percent, P/E 20.14, market capitalization USD 11.2 billion on October 20, 2026.

Valuation and trading context

Haemonetics had a market capitalization of USD 5.4 billion and a P/E ratio of 58.25 on October 20, 2026. Its NYSE quote stood at USD 118.83 at 1:52 p.m. EDT, with a reported intraday range of USD 117.50 to USD 120.45 and volume of 207,925 shares.

Haemonetics stock was trading at EUR 105.50 at Lang & Schwarz on October 20, 2026 at 7:47 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Haemonetics stock.